| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2007;49:e12.)
© 2007 American Heart Association, Inc.
Letters to the Editor |
Department of Clinical Medicine, University "La Sapienza", Rome, Italy
We have read with great interest the article by Ryan et al.1 We agree with the authors that the NZBWF1 strain may be an important model to study the effects of obesity and insulin resistance on systemic lupus erythematosus (SLE)associated hypertension. The authors have observed that this hypertensive mouse model of SLE has an increased body weight, central adiposity, plasma leptin, and insulin resistance. The relationship between SLE and insulin resistance is not clear. As suggested by the authors, the autoimmune pathogenesis of insulin resistance in subjects with SLE is rare. Lagana et al2 have shown that an autonomic dysfunction characterizes SLE patients with and without microvascular disease. We suggest a possible role for mechanisms as the activation of the autonomic nervous system in the development of hypertension and insulin resistance and in the change in body composition in SLE patients. The autonomic nervous system modulates glucose and fat metabolism. Recently, a prospective cohort study3 revealed a high relative risk to develop type 2 diabetes if autonomic dysfunction is present in healthy subjects independent from other risk factors. Kreier et al4 propose an unbalanced and arrhythmic autonomic nervous system as a major cause of the metabolic syndrome, and, in a previous study,5 we propose that an impairment in the autonomic nervous system activity could precede the development of insulin resistance and type 2 diabetes mellitus. In conclusion, we hypothesize that the SLE is characterized by an autonomic dysfunction that could affect the glucose metabolism, and it could cause insulin resistance and change in body composition in these patients. We suggest that the authors test this hypothesis.
| Acknowledgments |
|---|
None.
| References |
|---|
|
|
|---|
2. Lagana B, Schillaci O, Tubani L, Gentile R, Danieli R, Coviello R, Baratta L, Scopinaro F. Lupus carditis: evaluation with technetium-99m MIBI myocardial SPECT and heart rate variability. Angiology. 1999; 50: 143148.[Medline] [Order article via Infotrieve]
3. Carnethon MR, Golden SH, Folsom AR, Haskell W, Liao D. Prospective investigation of autonomic nervous system function and the development of type 2 diabetes: the Atherosclerosis Risk In Communities study, 19871998. Circulation. 2003; 107: 21902195.
4. Kreier F, Yilmaz A, Kalsbeek A, Romijn JA, Sauerwein HP, Fliers E, Buijs RM. Hypothesis: shifting the equilibrium from activity to food leads to autonomic unbalance and the metabolic syndrome. Diabetes. 2003; 52: 26522656.
5. Fiorentini A, Perciaccante A, Paris A, Serra P, Tubani L. Circadian rhythm of autonomic activity in non diabetic offsprings of type 2 diabetic patients. Cardiovasc Diabetol. 2005; 4: 1522.[CrossRef][Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
M. J. Ryan Response to Insulin Resistance and Obesity in a Mouse Model of Systemic Lupus Erythematosus Hypertension, February 1, 2007; 49(2): e13 - e13. [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |